We recently demonstrated that NEAT1 is up-regulated in MM [23] and its silencing antagonizes MM cell growth both in vitro and in vivo and affects the Homologous Recombination (HR) repair pathway, which may explain the synergistic impact with several drugs, including bortezomib (BTZ), carfilzomib, melphalan, and PARP inhibitors [24]. The gene discussed is NEAT1; the disease is Miyoshi myopathy.